Tracking Symptoms Over Time in Adults With Stage IIB to IV Cutaneous Melanoma Receiving Immune Checkpoint Inhibitor Therapy

What this Trial Is About

Researchers are studying how immune checkpoint inhibitors ICIs, a type of treatment for stages IIB to IV cutaneous melanoma, affect patients symptom experiences over time. This observational study aims to understand different symptom patterns and identify factors like demographics, clinical status, environment, and molecular markers that might be linked to worse symptoms. Filling this knowledge gap will help improve symptom management and guide treatment decisions for patients with this common skin cancer. Participants are adults diagnosed with stage IIB to IV cutaneous melanoma who will be receiving immune checkpoint inhibitor therapy as part of their usual care. The study involves reviewing medical charts from the start of their treatment for up to four cycles. Participants may also complete health-related quality of life questionnaires and provide blood samples during regular clinic visits to support research on symptom experiences. Throughout the study, participants will be monitored for the frequency and types of symptoms they report up to five months after treatment begins. The research team will analyze symptom profiles and explore risk factors for worse symptom experiences. Blood samples and questionnaires collected at clinic visits will help track changes in symptoms and quality of life. The total participation duration varies with ongoing data collection during the initial treatment phase.

Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma